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Response to letter of Dr Zanen re:
paper by Milanowski et al. (Respir
Med 1999; 93: 245±251)We thank Dr Zanen for his reasoned statistical comments
on the studies (1,2). However, the aim of the two studies
was to demonstrate therapeutic equivalence between the
BDP-CFC and BDP-HFA inhalers based on meaningful
clinical dierences in everyday practice. Unfortunately, Dr
Zanen’s assumption that equivalence was based on a lack of
statistically significant dierences between the two prepara-
tions is incorrect given that the conclusions of equivalence
were derived from comparisons of confidence intervals for
the between-treatment dierence and an acceptable range
considered to be clinically equivalent.
The significant and equivalent improvements in lung
function and asthma symptoms seen with both BDP-CFC
and BDP-HFA in these studies are entirely consistent with
the literature on similar inhaled steroid studies. Minor
numerical dierences in lung function indices and standard
deviations between populations are unlikely to matter in
clinical practice, as has been borne out by successful
transfer of asthma patients from the BPD-CFC to the
BDP-HFA inhaler on a 1:1 dose basis since introduction of
the latter product to the market in Ireland 18 months ago.
We reiterate our belief that the sample sizes chosen in
these studies were based on clinically relevant dierences
and that the products are indeed equivalent in both
meaningful statistical terms and in clinical practice.
V. L. PERRIN, D. W. FAKES AND
D. UNDERWOOD
Norton Healthcare Ltd and Statwood Partnership
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Inhaled beclomethasone (BDP) with
non-CFC propellant (HFA-134a) is
equivalent to BDP-CFC for the
treatment of asthma: Milanowski
et al. (Respir Med 1999; 93: 245±251)I read with interest the paper from Milanowski et al. on the
equivalence of BDP-HFA to BDP-CFC. This is based on
two studies, one low dose (400 mcg day71 BDP) and one
high dose (2000 mcg day71). The results of these studies I
think should be viewed with caution but open up some
interesting areas of debate.
The statistical analysis for both studies was based on
testing for dierence. This was defined as a dierence in
mean pre-dose FEV1 of 402 l. The results clearly show
that the 90% confidence interval for the high dose study
(7034–05) lies outside +02 l. Similarly for the low dose
study the 90% confidence interval is (7014–035), again
lying outside the upper end of the pre-defined +02 l.
It is stated that the total number of patients needed to
detect a statistical dierence with 90% power using 90%
confidence intervals was 100. The standard deviation for
FEV1 in both studies was around 08 l. To detect
equivalence or dierence, based on these assumptions, the
total number of patients needed would be 275 and 338 per
treatment group respectively, greatly in excess of 100. It
would therefore appear that these studies are both under-
powered and inconclusive. Consequently the interpretation
by Milanowski et al. that BDP-CFC and BDP-HFA
(Norton Healthcare Ltd, U.K.) are clinically and statisti-
cally equivalent should be viewed with caution.
The dosing schedule of qds dosing is not in line with the
British Asthma Guidelines and would have led to poor
compliance in some subjects. The rationale behind this
schedule needs to be justified. In the high dose study a very
wide-ranging group of patients (taking 800–2000 mcg day
BDP71) were randomized to 2000 mcg of either BDP-HFA
or BDP-CFC patients. This wide variability may account
for the large confidence intervals seen in this study, but
underlies the need to conduct robustly designed ecacy and
safety studies as well as dose response studies.
The study also considers safety, as measured by adverse
events and am plasma cortisol. Morning plasma cortisol is
a very variable measure and studies using 24 h urinary free
cortisol would be a more helpful measure to define any
clinically relevant dierence between the two formulations.
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